Author: Justin Mckibben
It seems politicians are telling people- take your pick; guns or marijuana… you can’t have both.
Back in 2016, you may recall that we did an article covering the story of S. Rowan Wilson, a Nevada resident who in 2011 was denied when attempting to purchase a handgun when the gun store owner recognized her as a medical marijuana cardholder. In court, Wilson maintained that she does not herself use marijuana, but in August of 2016, the 9th U.S. Circuit Court of Appeals decided in a 3-0 vote that if you have a medical marijuana card, you can’t buy a gun.
Recently the ideas behind this case have sparked renewed outrage and discussion over whether or not medical marijuana users should be permitted to own a firearm. The gun control debate is one that is already being consistently argued in the shadow of recent mass shootings and pushing from politicians to address the issue. But drug policy impacting gun policy adds a new perspective to the conversation.
Now there are several states cracking down on marijuana users, and it has some people up in arms about how even though states are legalizing medical marijuana use, federal law and many state governments are cutting them off from their right to gun ownership.
Under Federal Influence
According to federal law, gun purchases are already prohibited to people who are described as:
“-unlawful user and/or addict of any controlled substance.”
Back in 2011, the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) insisted that the law applies to marijuana users-
“regardless of whether [their] State has passed legislation authorizing marijuana use for medicinal purposes.”
So it seems the ATF and the federal government are pulling out all the stops when it comes to making sure marijuana users aren’t allowed to own guns.
The decision in the care of Wilson and the 9th U.S. Circuit Court of Appeals includes the areas:
- District of Alaska
- District of Arizona
- Central District of California
- Eastern District of California
- Northern District of California
- Southern District of California
- District of Hawaii
The Supreme Court ruled that it is NOT a violation of 2nd Amendment Rights to deny guns to marijuana patients. The impact of that ruling has now begun to spread. It would seem the federal government thus far is standing by this. Special Agent Joshua E. Jackson of the U.S. Bureau of Alcohol, Tobacco, Firearms and Explosives in Washington D.C. states:
“There are no exceptions in federal law for marijuana used for medicinal or recreational purposes.”
And as far as things look now, there will be no change anytime soon to the federal government’s stance on marijuana. Especially with the current administration emphasizing so heavily a law and order approach to drug policy.
More States Against Marijuana and Guns
Even though there are 29 states and Washington D.C. that have voted to allow patients to have access to medical marijuana, several of these states are choosing to trade that opportunity for a shot at gun ownership. In fact, just this week a few state officials announced their own stance against allowing gun owners to be medical marijuana patients.
In a move that spurred a backlash of viral videos and other reports, Hawaii took a bold step in this effort. Last week the Honolulu Police Department sent letters to medical marijuana users saying that they will need to turn in their weapons within 30 days of receipt. According to Leafly, a copy of one of these letters states:
“Your medical marijuana use disqualifies you from ownership of firearms and ammunition.”
However, the letter also apparently says that the medical marijuana patients can get their firearms back. The stipulation being they would need a doctor’s clearance to do so.
A similar situation happened in Pennsylvania. The state police director of the Bureau of Records and Identification, Major Scott C. Price, made an announcement on Tuesday stating:
“So, in fact, an individual who is issued a medical marijuana card in Pennsylvania who is a user of medical marijuana, that individual would be prohibited from purchasing or technically possession of a firearm under federal law.”
So Pennsylvania won’t allow people to even be in possession of a firearm at any time with a medical marijuana card.
Ohio’s medical marijuana program becomes operation in September of 2018. Information from industry analysts estimate that 24% of the state’s population have qualifying conditions; that’s 2.8 million Ohioans. But just this week it was announced that people in the Buckeye State who register to legally use marijuana for medicinal purposes will also be prohibited from possessing firearms.
According to the ATF letter from back in 2011, marijuana users are also prohibited from:
- Possessing firearms or ammunition
So anyone in Ohio who is applying to purchase a gun from a licensed dealer must sign a form attesting her or she is not “an unlawful user of, or addicted to, marijuana or any depressant, stimulant, narcotic drug, or any other controlled substance.”
Under federal law, lying on the form is a felony punishable by up to 10 years in prison. Even Joe Eaton, southwest spokesman for the Buckeye Firearms Association says they are confused at this point,
““There is definitely a conflict between the state laws and the federal laws,”
Some Ohio law enforcement officials are also unsure at this point how to enforce these situations as of the moment, and are depending on their prosecutors to provide more clarification through the conflict with state and federal law.
Will Marijuana Users Go Molon Labe?
For those unfamiliar with the term, molon labe is Greek for “come and take [them]”. This declaration has been repeated by many generals and politicians to express an army’s or nation’s determination not to surrender. The motto ΜΟΛΩΝ ΛΑΒΕ is on the emblem of the I Army Corps of Greece and the Second Infantry Division of Cyprus, and is also the motto of United States Special Operations Command Central (SOCCENT). The expression “Come and take it” was a slogan in the Texas Revolution.
It is also a popular choice of words for many 2nd Amendment advocates.
The question becomes, how will the hardcore 2nd Amendment supporters react to this ruling against medical marijuana and guns? Some actually believe this may actually inspire the National Rifle Association (NRA) to become pro-medical marijuana at the federal level. Will this kind of shift in support turn the tide?
Will avid gun owners come out in strong opposition to taking away guns from medical marijuana patients, or will they agree that drug use should disqualify them from owning or possessing weapons and ammunition?
How should authorities proceed? Is this a safe political sit rep or another war of opinions waiting to happen?
Treating Marijuana Abuse
Whether or not you support gun ownership of medical marijuana patients, we should all be able to get behind having treatment resources for anyone who struggles with substance abuse.
Marijuana, much like any other substance, can be abused and have an adverse impact on the overall quality of life for many people. No matter what the legal status of any drug, it can still have a negative impact on people who grapple with substance use disorder. We know this all too well, as plenty of prescription medications helped create the opioid crisis in America.
There still needs to be resources available to help people who suffer from abuse. Supporting addiction recovery means breaking the stigma and offering holistic and effective solutions. Palm Healthcare Company is here to help. If you or someone you love is struggling, please call toll-free now.
CALL NOW 1-800-951-6135
(This content is being used for illustrative purposes only; any person depicted in the content is a model)
Author: Justin Mckibben
You may remember back in early 2016 the pharmacy organization Walgreens announced two programs to address key issues in the opioid crisis.
- Safe medical disposal kiosks for unused prescription drugs
- Narcan expansion programs
By the end of 2016, Walgreens had expanded access to the opioid overdose antidote without the requirement of a prescription to 33 states and the District of Columbia. The Narcan opioid overdose antidote, also known by the generic name Naloxone, is a nasal spray that is utilized all over the country as a means to revive someone experiencing an opioid overdose.
Now, this life-saving compound is becoming even more accessible, as Walgreens is announcing the Narcan opioid overdose antidote will now be available at all of its over 8,000 pharmacy locations!
Pharmacies Stepping Up to the State of Emergency
This new move to combat the opioid epidemic comes at a crucial time. The epidemic continues to claim lives every day, with recovery advocates and government officials rallying for more resources to fight the problem.
Today, Thursday, October 26, 2017, the nation is expecting President Donald Trump to officially declare the opioid crisis a public health emergency at a scheduled White House event.
According to Rick Gates, Vice President of Walgreens,
“By stocking Narcan in all our pharmacies, we are making it easier for families and caregivers to help their loved ones by having it on hand in case it is needed.”
The company offers Narcan opioid overdose antidote without a prescription in 45 states and is willing to work with the remaining states to make to include them.
Of course, the fight for more availability of Narcan and Naloxone has been going on for some time. However, it seems as the country is calling for more sweeping action from government officials; pharmacies are taking it as a call to action themselves. Rick Gates went on to say,
“As a pharmacy, we are committed to making Narcan more accessible in the communities we serve.”
Walgreens also says it will inform customers about the Narcan opioid overdose antidote if they receive drugs with more than 50 morphine milligram equivalents (MME). This is actually a recommendation from the CDC.
It isn’t just Walgreens either. CVS pharmacy has expanded access to Narcan and other products that contain naloxone. CVS reportedly has been offering prescription-free naloxone in up to 43 states as of last month. CVS pharmacies have said that its locations “in most communities have naloxone on hand and can dispense it the same day or ordered for the next business day.”
Big Pharma’s Role
Big Pharma wholesaler AmerisourceBergen is also helping in these efforts. AmerisourceBergen is now distributing Narcan demo devices at no cost to Walgreens pharmacists. These demo devices will help with instructing patients on how to administer the medication safely and effectively.
Robert Mauch, Executive Vice President & Group President, Pharmaceutical Distribution & Strategic Global Sourcing for AmerisourceBergen, states,
“At AmerisourceBergen, we strive to provide our customers the highest quality care and support so they can ultimately enhance the lives of patients in their communities,”
“We recognize the important role we play in addressing the opioid epidemic, and our collaboration with Walgreens is another key milestone to supply our customers with access to lifesaving initiatives and emergency medications that can help keep individuals safe across the country.”
Ironically, AmerisourceBergen just so happens to be one of the three largest drug distributors that were mentioned in the recent 60 Minutes interview with ex-DEA agent Joe Rannazzisi. In the segment that has since caused a major uproar, Rabbazzisi said companies including AmerisourceBergen controlled probably 85%- 90% of drugs that went “downstream” and ended up on the streets.
This might not be what Mauch meant by “recognize the important role we play”, but at least it seems like AmerisourceBergen is taking steps to become part of a solution.
Meanwhile, Adapt Pharma, the manufacturer of Narcan Nasal Spray, celebrates this action by Walgreens to expand naloxone and Narcan access. Seamus Mulligan, CEO at Adapt Pharma states,
“This action is an important milestone and we applaud Walgreens initiatives to improve access to Narcan Nasal Spray in communities across the U.S.,”
“This effort, combined with the opportunity for patients and caregivers to obtain Narcan Nasal Spray without an individual prescription in 45 states, is critical in combating this crisis.”
America is working hard to find the right path on the road to recovery from the devastating opioid crisis. It is crucial that we make every possible resource available to help save lives. With opioid overdose killing an estimated 91 people every day, the need for this life-saving medication could not be more evident.
Beyond reversing the effects of an overdose, there is more we need to do. While having access to Narcan and naloxone can help tremendously, we also need to promote recovery and addiction treatment resources. Preservation of life is important, but giving people the help they need to live a happier and healthier life should also be a priority in the fight to overcome the opioid crisis. Palm Partners Recovery Center believes in actively providing the best in innovative and holistic treatment opportunities, to help transform lives. If you or someone you love is struggling with substance abuse or addiction, we want to help. Please call toll-free now.
CALL NOW 1-800-951-6135
Author: Justin Mckibben
Earlier this week we talked about a story that shook things up in politics as a former DEA agent threw some serious accusations at the Big Pharma industry, Congress and a number of key officials for their involvement in policies some believe helped create the enduring opioid crisis in America. Among those accused of tipping the scales in favor of Big Pharma and stripping power away from those charged with regulating the industry was Republican Representative Tom Marino.
Of course, we know that Tom Marino was President Donald Trump’s top nominee to be the nation’s drug czar.
Now, after withdrawing from the nomination to head the White House Office of National Drug Control Policy, Tom Marino says he is proud of his role in writing a 2016 law that many critics say paved the way for the current epidemic.
The Tom Marino Factor
What kind of role did Tom Marino have in the creation of the Ensuring Patient Access and Effective Drug Enforcement Act? Why is it that so many are up in arms about the bill in the first place?
To recap- Pennsylvania Congressman Tom Marino and Congresswoman Marsha Blackburn of Tennessee introduced a bill to the House. It was advertised to officials as a way to ensure that patients had access to the pain medication they needed. In a statement released by Marino’s office, he claims the law would help “facilitate a balanced solution” by ensuring access to certain medications while allowing the Drug Enforcement Administration to prevent the sale and abuse of prescription drugs.
In essence, Tom Marino was supposedly pushing for a way to let pain management patients still get the useful medications they needed, without impeding on the process of curbing abuse.
But that isn’t how everyone sees it, especially after the 60 Minutes story.
Why it Matters
According to the opposition, the bill ultimately did little else besides weaken the DEA and the government’s authority to stop companies from distributing opioids in suspicious shipments.
For years prior to the passage of the “Marino Bill” some big-time drug distributors were getting fined thousands of dollars for repeatedly ignoring DEA warnings to shut down suspicious sales of hundreds of millions of pills. These companies were racking up billions of dollars in sales while turning a blind eye to obnoxious overprescribing of dangerous drugs.
Back then the DEA was able to immediately prevent drugs from reaching the street by freezing suspicious shipments. If the DEA judged that the drugs posed an “imminent danger” to a community, they could take action to prevent the flood of powerful narcotic medications from overwhelming the area.
However, the Tom Marino bill is argued to make it virtually impossible for the DEA to freeze suspicious narcotic shipments from the companies. Now, the agency is required to demonstrate that a drug distributor’s actions represent “a substantial likelihood of an immediate threat,” which officials say is far more difficult criteria to meet. The report against the Tom Marino bill even cited internal DEA and Justice Department documents and an independent assessment by the DEA’s chief administrative law judge.
The DEA even fought the bill, according to people within the agency, but in 2015 the law gained momentum again when the Justice Department named a new chief of the DEA- Chuck Rosenberg. After some reluctance, the report on 60 Minutes that included exclusive insight from Joseph T. Rannazzisi states the DEA ultimately took a deal they did not want.
Champion for Big Pharma
Marino disputed that, calling the reports “false accusations and unfair reporting.”
Tom Marino spent years pushing versions of this bill through Congress. He argued that it was to put an overly-aggressive DEA in check and protect drug companies from what he believed was unfair or misguided federal interference. In other words, he spent a lot of time fighting for Big Pharma’s ability to send millions of pills to communities that didn’t have half the population to justify them. All because the DEA was being aggressive?
The irony here is that the same people who pushed so hard for drug distributors ability to traffic obscene among of pills without the pesky DEA would probably be the same people demanding mandatory minimums for low-level drug offenders on the streets.
And again, many are still suspicious of those involved in pushing for this kind of legislation because of their connections to Big Pharma industry. The Post reports that the drug industry worked behind the scenes with lobbyists and key members of Congress, including Tom Marino.
Some reports indicate the Big Pharma industry poured more than a million dollars into election campaigns, including Marino’s, who received nearly $100,000 in campaign contributions from political action committees supporting the drug industry.
Utah Republican Senator Orrin Hatch calls the report “complete baloney” after it gained serious momentum earlier in the week.
Why are we not surprised? Because Hatch himself has received hundreds of thousands in donations from Big Pharma companies and health contributors over the years.
Holding Big Pharma accountable for their contribution to the opioid epidemic has become an increasingly popular cause. Lawyers and politicians at all levels have been pushing to put a spotlight on the shady side of the pharmaceutical industry. Now it seems that spotlight may extend more and more to exposing the politics that allow these issues to spread.
Another crucial element to putting an end to the opioid epidemic is providing safe and effective treatment for those who need help the most. A lot of people are still out there suffering because of prescription drug abuse or other dangerous substances. But we want to help. If you or someone you love is struggling, please call toll-free now.
CALL NOW 1-800-951-6135
Author: Justin Mckibben
Ever since the true nature of the opioid epidemic in America began to come to light, and people started to see the gravity of its impact in communities across the country, there have been plenty of efforts to find out how we ever got this far. We continue to ask who should be held accountable. Was it the black market drug trade? Was it the synthetic opioids coming from overseas? How did it get this bad?
Just this past week 60 Minutes and The Washington Post joined forces to interview Joe Rannazzisi, who is said to be the most important whistleblower ever on 60 Minutes.
Joe Rannazzisi is a former agent of the Drug Enforcement Administration (DEA) who ran the Office of Diversion Control; the department in charge of regulating and investigating the pharmaceutical industry. He is a former DEA deputy assistant administrator with a law degree, and a pharmacy degree, who believes the great injustice done to the American people cannot go overlooked.
Bad Business with Big Pharma
Through this inside look with Rannazzisi, he implicates Big Pharma drug makers in willingly distributed hundreds of millions of drugs to rogue pharmacies and pain-clinics-turned-pill-mills for over two decades.
Rannazzisi believes that the Big Pharma companies, some even multi-billion, Fortune 500 companies, have contributed to the problem by ignoring the truth; that powerful prescription pain medications were being diverted from doctors, clinics and pharmacies for illicit use. In the interview, Rannazzisi calls out a number of key drug makers, including:
He also calls out the three largest drug distributors:
- Cardinal Health
Saying they control probably 85%- 90% of drugs “going downstream.”
In fact, Rannazzisi said the way pain clinics seemed to pop up overnight all over the country made the whole crack-cocaine epidemic look like nothing, saying he had never seen anything like it, adding:
“These weren’t kids slinging crack on the corner. These were professionals who were doing it. They were just drug dealers in lab coats.”
Rannazzisi says after prosecuting pain doctors and pharmacists didn’t seem to put a real dent in the problem, he knew he had to work his way up; they went after distributors.
While drug distributors tried to defend themselves saying it was all on the doctors for over-prescribing medications, Rannazzisi says they know exactly how many pills are being sent out. Under the Controlled Substances Act, these distributors are required by law to report and stop what the DEA refers to as “suspicious orders”.
So what might “suspicious orders” look like? Probably something lie unusually large and/or frequent shipments of opioids being made to a location. Kind of like what was happening all over the nation for years and years.
For example, just one pharmacy in Kermit, West Virginia ordered 9 million hydrocodone pills in just over 2 years. That’s for a town of only 392 people. That’s over 11,479 pills a person each year! Almost 1,000 pills a month! From only one of the town’s pharmacies.
DEA investigators say many drug distributors ignored the DEA requirements and shipped anyway.
DEA Fighting Back
Rannazzisi wasn’t the only DEA agent to speak up about Big Pharma’s bad business. Several other DEA veterans say they saw thousands of suspicious orders and tried to fight the growing problem. Others said they tried on multiple occasions to get these companies to fix the issue, but they did nothing.
Eventually, in 2008 the DEA was able to hit some distributors with hefty fines for filing hundreds of suspicious orders, including:
- $13.2 million fine against the country’s largest drug distributor, McKesson
- $34 million fine against second-largest distributor, Cardinal Health
The fines for drug distributors over the last 7 years add up to around $341 million.
The High Rollers
In 2011, Cardinal Health attorneys called Rannazzisi’s boss at the Justice Department, who called Rannazzisi and pressed for an explanation for his policies. Rannazzisi believes that even after they had gone after small companies hundreds of times before, as soon as they went after the Fortune 500 drug makers, their power and influence started getting in his way.
Rannazzisi says that with these massive Big Pharma empires there was now money and influence being used to pressure top lawyers at the DEA to pursue a softer approach on penalizing drug distributors who broke the rules.
Former DEA attorney Jonathan Novak noticed that shocking shift in the way these kinds of cases were handled. Stating:
“These were not cases where it was black — where it was grey… These were cases where the evidence was crystal clear that there was wrongdoing going on.”
But suddenly the higher ups started to demand more and more evidence to stall the system. Fewer cases against Big Pharma companies were being approved, and road-blocks from Novak’s bosses seemed to pop up everywhere.
Novak also said he saw a huge migration of DEA lawyers switching sides to defend the drug industry in higher paying positions.
Taking it to Congress
While drug distributors started successfully stalling the progress of cases against them from the DEA, they also began to lobby Congress to get legislation that would destroy the DEA’s power over them.
Then one day Pennsylvania Congressman Tom Marino and Congresswoman Marsha Blackburn of Tennessee introduced a bill to the House that was promoted as a way to ensure that patients had access to the pain medication they needed. However, Jonathan Novak, who worked in the DEA’s legal office, claims that what the bill really did was strip the agency of its ability to immediately freeze suspicious shipments of prescription narcotics to keep drugs off U.S. streets.
The bill’s author… Linden Barber, a former employee of the DEA.
Congressman Tom Marino, along with Congresswoman Blackburn, later wrote the inspector general for the Justice Department, demanding that Rannazzisi be investigated for trying to quote “intimidate the United States Congress.” Even though this went nowhere, Rannazzisi was stripped of his responsibilities soon after.
Some former DEA agents believe that the Big Pharma industry not only used lobbying groups to donate money to politicians to get laws passed in their favor, but also to try and push Joe Rannazzisi out of his office.
In the end, the DEA signed off on the final version of the “Marino bill.” A senior DEA representative claiming that even though they fought to stop it, growing pressure from Congress and industry lobbyists forced them into a deal it did not want.
The bill was presented to the Senate in March of 2016.
Majority Leader Mitch McConnell introduced the legislation in the Senate.
It passed by unanimous consent with no objections and no recorded votes.
It passed the House the same way, and President Obama signed it into law.
Where Are We Now?
This whole thing reminds you of the saying- if you can’t beat em, join em.
It would seem that’s exactly what a lot of DEA agents did after fighting a losing battle against powerful Big Pharma companies.
Since it all began, the pharmaceutical industry and law firms that represent them have hired at least 46 investigators, attorneys, and supervisors from the DEA, including 32 directly from the division that regulates the drug industry.
Remember that guy Linden Barber, who authored the bill that many say stripped the DEA of the power to go after Big Pharma companies? Well 3 months ago Cardinal Health, that second-largest drug distributor we were talking about that went after Rannazzisi through his boss, hired Linden Barber as the senior vice president!
Other former DEA agents and lawyers have gone on to take up so pretty prestigious positions working for drug companies, or law firms and other organizations working in the pharmaceutical industries best interest.
Joe Rannazzisi now consults with state attorneys general who have filed suit against distributors for their role in the opioid crisis.
Oh… and let us not forget Congressman Marino, who was just nominated to become President Trump’s new drug czar.
Remarkably, there are a lot of instances of people in the DEA being influenced by pharmaceutical companies and lobbyists to stand up for drug companies instead of the tens-of-thousands of Americans dying from opioids each year. In many of these instances, the individual’s go on to get high-earning jobs defending the interests of the Big Pharma industry.
So is it a made-up conspiracy? Or are pharmaceutical companies buying their way out of trouble at every turn and pushing out people like Rannazzisi who stand up to them? Is it really that hard to believe when you connect the dots?
With an ongoing opioid epidemic doing major damage to the country, we have to acknowledge everything that has contributed to this issue. Even if we set aside the idea of placing blame, we cannot prevent it from getting worse or happening again if we don’t acknowledge what helped cause it. Every drug company, policy maker, pharmacy, crooked doctor and individual should be accountable to taking action to make things better. It starts with accepting the issue and building a foundation to recover. If you or someone you love is struggling, please call toll-free now. We want to help.
CALL NOW 1-800-951-6135
Author: Justin Mckibben
The Global Commission on Drug Policy (GCDP) is an international institution of global leaders and intellectuals working to help study and inform initiatives on addressing drug use all around the world. This think tank offers recommendations concerning drug use and its consequences for societies across the globe.
The GCDP consists of members from various nations, including but not limited to:
- The United States of America
- The United Kingdom
Former U.S. President Jimmy Carter wrote an op-ed in The New York Times explicitly endorsing the recommendations of the Global Commission on Drug Policy, and the group has released various reports over the years focusing on the efforts to curb the spread of drug abuse.
Recently the GCDP released a position report on the North American opioid epidemic. In this report, the commission issues recommendations that appear to endorse the expansion of harm reduction techniques to battle the ongoing crisis.
The Turning Point for America
According to the GCDP’s new report, North America is at a turning point in the way that drug addiction is viewed. This is not too much of a surprise, considering now more than ever there has been a push for a more compassionate perspective on drug use and addiction. America now finds itself in a unique position where the stigma that has so long been attached to addiction is starting to be abandoned, and more progressive action is being taken.
Now the Global Commission on Drug Policy believes national policymakers should take advantage of this unique opportunity to reduce opioid-related deaths through harm reduction. In the report the authors state:
“While in recent years media and politicians have been more open to viewing addiction as a public health problem, leadership is needed to turn this into an urgent and commensurate response to the crisis,”
One way that the Global Commission on Drug Policy ideals clashes with that of the Trump administration, currently steering drug policy in America is that the GCDP does not endorse the old policies of the War on Drugs.
GCDP vs War on Drugs
Back in June of 2011, the GCDP stated:
“The global war on drugs has failed, with devastating consequences for individuals and societies around the world.”
Again, this recent report echoes that sentiment, saying that attempting to cut off the opioid supply is not the answer. The new report notes how this approach has been tried before, as the first reactions to the opioid epidemic were to limit prescriptions and to introduce pills that were harder to manipulate.
The report goes on to note that this response drove people to use cheaper and often much more potent street drugs instead of prescription pills. Fentanyl is one of the worst synthetic opioids to contribute to the outbreak of overdoses and deaths across the country.
The Global Commission on Drug Policy says cutting off the supply of opioids into the country cannot be effectively executed until after supportive measures are put in place. This means supporting not only both people battling addiction but also people with chronic pain. The report insists:
“The aim is to achieve the right balance in regulation to provide effective and adequate pain care, while minimizing opportunities for misuse of these medications.”
To reduce the harmful impacts of opioids, the commission calling for the acceptance and implementation of harm reduction strategies.
The Global Commission on Drug Policy Suggests Harm Reduction
So if they are saying that the War on Drugs did not work, and neither will bulking up borders, then what will?
Well, according to the GCDP, harm reduction is the right move. The new report calls on American lawmakers to promote programs like:
Naloxone Distribution and Training
As the opioid overdose antidote, Naloxone is an invaluable tool to have in the fight against the opioid epidemic in America, but the price for the drug continued to skyrocket as the epidemic got worse. Making it more available could give access to and train people with life-saving medication to thousands or even millions more.
Safe locations where IV drug users can trade old, contaminated needles for new, sterile needles to help prevent the spread of blood-borne illness like HIV.
Facilities where drug users can go to use their drugs with sterile equipment safely, reducing the number of overdose deaths by providing a place free of punishment for them to use with medical emergency resources on site.
These kinds of programs would allow for users to check their drugs for the presence of any unknown substances it may have been diluted with. For example, most fentanyl users do not know they are using fentanyl.
Decriminalizing Drugs in America
In another aspect of the report, GCDP also makes a much more revolutionary and more radical suggestion that many may consider qualifying as harm reduction: decriminalization.
The report states:
“The Global Commission on Drug Policy also calls for the elimination of illicit drug markets by carefully regulating different drugs according to their potential harms. The most effective way to reduce the extensive harms of the global drug prohibition regime and advance the goals of public health and safety is to get drugs under control through responsible legal regulation.”
With this philosophy in mind, the GCDP made two more drastic recommendations:
- End the criminalization and incarceration of people who use drugs nation-wide in Canada and the United States.
- Allow and promote pilot projects for the responsible legal regulation of currently illicit drugs including opioids.
The idea is that by decriminalizing drugs, they can bypass criminal organizations and ultimately replace the current black market.
“Do not pursue such offenses so that people in need of health and social services can access them freely, easily, and without fear of legal coercion,”
We have begun to see a watered-down variation of this kind of strategy with many Police Assisted Addiction and Recovery Initiative (PAARI) programs, where law enforcement is helping addicts get into treatment instead of arresting them when they ask for help.
Better Treatment Research
The report insists that more research is necessary in a few critical areas in order the effectively address the opioid crisis and the overall drug problem in America.
One of the key points of research the GCDP proposes is for finding the most effective treatments for addiction, specifically to prescription opioids. In addition, the report shows support for medication-assisted treatment (MAT) and opioid substitution therapy (OST) as a means to preserve life to assist in the recovery process. While these programs are met with some of the same contentions as safe injection sites or decriminalization, the commission seems adamant about using harm reduction to keep people alive long enough to get better.
Michel Kazatchkine, a doctor and commission member, said in a recent interview:
“Repression is harmful. Wherever repressive policies are in place, people will not be in the best condition to access services.”
While he and other commission members are in no way naïve to the fact there is no way decriminalization will happen at the federal level soon in the U.S., they remain hopeful that states or cities will make decisions which don’t require federal approval, or for which they are willing to enter to fight with the federal process.
Overall, the hope of the GCDP is that these suggestions, coming from a group of world leaders fully invested in understanding the issue, will convince American and Canadian lawmakers to take a progressive approach to the crisis.
What could some of these changes mean for those trying to recover from opioid abuse? How could some of these ideas change the way addiction treatment operates within America?
One thing is for certain, in fighting opioid addiction, whether as a society, as a family or as an individual, there needs to be compassion and action. It takes courage and it takes a degree of uncertainty. But with the right resources, there is hope for a greater future. If you or someone you love is struggling with substance abuse or addiction, please call toll-free now.
CALL NOW 1-800-951-6135